Design and quality considerations for randomized controlled trials in systemic sclerosis

Arthritis Care and Research

Volumn 47, Issue 1, 2002, Pages 73-81

  Kyriakidi, Maria ^a   Ioannidis, John P A ^a,b  

^a UNIVERSITY OF IOANNINA   (Greece)

^b TUFTS UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Quality; Randomized controlled trials; Study design; Systemic sclerosis

Indexed keywords

ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; FOLLOW UP; HUMAN; METHODOLOGY; PATIENT COMPLIANCE; PATIENT SELECTION; QUALITY CONTROL; RANDOMIZATION; RANDOMIZED CONTROLLED TRIAL; RELIABILITY; SAMPLE SIZE; SCORING SYSTEM; SYSTEMIC SCLEROSIS; TREATMENT OUTCOME;

EID: 0036170270     PISSN: 21514658     EISSN: None     Source Type: Journal    
DOI: 10.1002/art1.10218     Document Type: Article

References (24)

1. Scleroderma
2. Outcomes measurement in scleroderma clinical trials
3. Guidelines for clinical trials in systemic sclerosis/scleroderma. I. Disease modifying interventions
4. Statistical methods for assessing agreement between two methods of clinical measurement
5. Assessing the quality of randomised controlled trials: An annotated bibliography of scales and checklists
6. Effect of the statistical significance of results on the time to completion and publication of randomized efficacy trials
7. Publication bias in clinical research
8. A consumer's guide to subgroup analyses
9. Completeness of safety reporting in randomized trials: An evaluation across 7 medical areas
10. Empirical evidence of bias. Dimensions of methodological quality associated with estimates of treatment effects in controlled trials
11. Subverting randomization in controlled trials
12. Can quality of clinical trials and meta-analyses be quantified?
13. The hazards of scoring the quality of clinical trials for metaanalysis
14. Improving the quality of reporting of randomized controlled trials. The CONSORT statement
15. Methodology and overt and hidden bias in reports of 196 double-blind trials of non-steroidal antiinflammatory drugs in rheumatoid arthritis
16. Sensitivity of effect variables in rheumatoid arthritis: A meta-analysis of 130 placebo controlled NSAID trials
17. Why do we need some large, simple randomized trials?
18. Bias in uncontrolled therapeutic trials in rheumatology due to selection of populations with extreme characteristics
19. High-dose versus low-dose D-penicillamine in early diffuse systemic sclerosis: Analysis of a two-year, double-blind, randomized, controlled clinical trial
20. Comparison of aminobenzoate potassium and placebo in the treatment of scleroderma
21. Oral iloprost treatment in patients with Raynaud's phenomenon secondary to systemic sclerosis: A muticenter, placebo-controlled, double-blind study
22. Long-term outcomes of scleroderma renal crisis
23. Outcomes of renal crisis in systemic sclerosis: Relation to availability of angiotensin converting enzyme (ACE) inhibitors